Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Oral Oncol. 2015 Jan 13;51(4):376–382. doi: 10.1016/j.oraloncology.2014.12.011

Table 2.

Number of patients with Grade 3 or 4 Toxicity in Arm A and B by CTCAE version 4.0

Cetuximab (Arm A) Cetuximab plus Sorafenib (Arm B)
Toxicity Grade 3 Grade 3 Grade 4
Fatigue 1 2 0
Infusion Reaction 1 5 3
Maculopapular Rash 1 2 0
Alkaline phosphatase 0 2 0
Anemia 0 1 0
Anorexia 0 1 0
AST increased 0 1 0
Diarrhea 0 2 0
Dyspepsia 0 1 0
Hypertension 0 1 0
Hypokalemia 0 1 0
Oral Mucositis 0 2 0
Nausea 0 1 0
Thromboembolic Event 0 1 0
Total 3 23 3
*

Grade 5 toxicites were not observed.